{
    "paper_id": "71e0c6ff69975a052762133489f734f576a3c3c0",
    "metadata": {
        "title": "An early test and treat strategy for SARS-CoV-2",
        "authors": [
            {
                "first": "Joshua",
                "middle": [
                    "T"
                ],
                "last": "Schiffer",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Vaccine and Infectious Diseases Division",
                    "institution": "University of Washington",
                    "location": {
                        "addrLine": "Fred Hutchinson Cancer Research Center 2",
                        "settlement": "Seattle"
                    }
                },
                "email": "jschiffe@fredhutch.org"
            },
            {
                "first": "Christine",
                "middle": [],
                "last": "Johnston",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Vaccine and Infectious Diseases Division",
                    "institution": "University of Washington",
                    "location": {
                        "addrLine": "Fred Hutchinson Cancer Research Center 2",
                        "settlement": "Seattle"
                    }
                },
                "email": ""
            },
            {
                "first": "Anna",
                "middle": [],
                "last": "Wald",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Vaccine and Infectious Diseases Division",
                    "institution": "University of Washington",
                    "location": {
                        "addrLine": "Fred Hutchinson Cancer Research Center 2",
                        "settlement": "Seattle"
                    }
                },
                "email": ""
            },
            {
                "first": "Lawrence",
                "middle": [],
                "last": "Corey",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Vaccine and Infectious Diseases Division",
                    "institution": "University of Washington",
                    "location": {
                        "addrLine": "Fred Hutchinson Cancer Research Center 2",
                        "settlement": "Seattle"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "As COVID-19 cases and deaths continue to expand globally, there is an urgent need to develop, test and approve effective antiviral therapies. Currently a majority of clinical trials are evaluating therapies in patients who are already hospitalized with SARS Co-V-2 infection. Given that the median time between development of symptoms and need for hospitalization is a week, a golden opportunity to intervene early is being missed. Indeed, for many other viral infections, early treatment soon after development of symptoms is associated with decreased mortality, lower hospitalization rates and lower likelihood of transmission to others. Here, we advocate for randomized double-blind placebo controlled clinical trials to evaluate promising agents early during SARS Co-V-2 infection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "The global community is enduring the horrific first wave of COVID-19. In many cities, emergency departments are inundated, and the pandemic continues to have a disproportionate effect on the elderly [1] [2] [3] . The only policy option is physical distancing to \"flatten the curve\" and decrease incident cases [4] . What follows the first wave will be a difficult balancing act. Full relaxation of physical distancing will allow a rapid surge of SARS CoV-2 infections [5] . Yet, the economy and supply chain may not tolerate sustained or recurrent shutdowns. Until there is widespread implementation of an effective vaccine, continued COVID-19 cases are inevitable.",
            "cite_spans": [
                {
                    "start": 199,
                    "end": 202,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 203,
                    "end": 206,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 207,
                    "end": 210,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 310,
                    "end": 313,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 468,
                    "end": 471,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "M a n u s c r i p t"
        },
        {
            "text": "To manage the pandemic, effective strategies are needed to treat infection and lower its fatality rate. To this end, the biology of SARS CoV-2 provides a golden opportunity to diagnose and treat, before infection becomes uncontrollable. The average time between development of symptoms and requirement for hospitalization is 7 days [6] , and to death is 14-21 days [7] . Viral kinetic studies demonstrate that early infection consists of a 2-3 day surge in viral loads, followed by a slow decline that persists for 2-8 weeks [8] [9] [10] . Initial symptoms develop around the period of maximum viral load and represent an optimal time to intervene (Figure) .",
            "cite_spans": [
                {
                    "start": 332,
                    "end": 335,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 365,
                    "end": 368,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 525,
                    "end": 528,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 529,
                    "end": 532,
                    "text": "[9]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 533,
                    "end": 537,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                }
            ],
            "ref_spans": [
                {
                    "start": 648,
                    "end": 656,
                    "text": "(Figure)",
                    "ref_id": null
                }
            ],
            "section": "M a n u s c r i p t"
        },
        {
            "text": "Symptoms often start in the upper respiratory tract and progress to dyspnea [8] . As was demonstrated for influenza in immunocompromised hosts [11] , elimination of viral replication during this early period may prevent progression to significant lung disease. If widely implemented in vulnerable populations such as the elderly, an early test and treat approach, applied at home, could lower case fatality and hospitalization rates.",
            "cite_spans": [
                {
                    "start": 76,
                    "end": 79,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 143,
                    "end": 147,
                    "text": "[11]",
                    "ref_id": "BIBREF10"
                }
            ],
            "ref_spans": [],
            "section": "M a n u s c r i p t"
        },
        {
            "text": "Much like managing an epidemic is more challenging when a city has 10,000 cases rather than 10, managing a SARS CoV-2 lung infection is more difficult when the entire tissue is overrun with virus, rather than a small portion. There is a longstanding precedent that early treatment of viruses leads to better outcomes. In a trial of Ebola treatment, shorter symptom duration at presentation correlated with lower viral load, and increased the likelihood that interventions would be life-saving [12] . Early influenza treatment causes shorter duration of shedding and symptoms [13] . For HIV, early treatment confers mortality benefits and lowers community transmission [14, 15] .",
            "cite_spans": [
                {
                    "start": 493,
                    "end": 497,
                    "text": "[12]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 575,
                    "end": 579,
                    "text": "[13]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 668,
                    "end": 672,
                    "text": "[14,",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 673,
                    "end": 676,
                    "text": "15]",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": "M a n u s c r i p t"
        },
        {
            "text": "The benefits of early test and treat may not be limited to the elderly. Life-threatening COVID-19 occurs in young, previously healthy people, particularly health care staff and transit workers who may be exposed to high viral inoculums [16] . Even among those who recover, symptoms can persist for weeks leading to multiple lost work days [17] . Early treatment could provide benefit to those not at risk for hospitalization.",
            "cite_spans": [
                {
                    "start": 236,
                    "end": 240,
                    "text": "[16]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 339,
                    "end": 343,
                    "text": "[17]",
                    "ref_id": "BIBREF16"
                }
            ],
            "ref_spans": [],
            "section": "M a n u s c r i p t"
        },
        {
            "text": "Widespread early treatment could also mitigate local epidemics. While a proportion of SARS CoV-2 transmission is attributed to asymptomatic and pre-symptomatic viral shedding, many transmissions result from coughing and sneezing leading to airborne droplets. Household viral load is a determinant of transmission for human herpesviruses [18] . Therapeutic reduction in shedding is linked with less transmission for herpes simplex virus-2 [19] . Lowering viral load is a mainstay of HIV prevention [20] . Even though shedding duration and transmissibility is shorter for influenza than SARS CoV-2, early oseltamivir initiation limits the secondary attack rate to household contacts. [21] Despite multiple advantages of treating early, nearly all ongoing trials are focused on hospitalized patients. At this later stage of COVID-19, while viral replication may augment disease progression, cytokine storm is an increasingly relevant aspect of pathogenesis, which is reflected by the use of biologics in the critically ill [22] , A c c e p t e d M a n u s c r i p t and incomplete efficacy of antiviral agents [23] . A rational therapeutic approach would prevent critical illness altogether.",
            "cite_spans": [
                {
                    "start": 337,
                    "end": 341,
                    "text": "[18]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 438,
                    "end": 442,
                    "text": "[19]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 497,
                    "end": 501,
                    "text": "[20]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 682,
                    "end": 686,
                    "text": "[21]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1020,
                    "end": 1024,
                    "text": "[22]",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 1107,
                    "end": 1111,
                    "text": "[23]",
                    "ref_id": "BIBREF22"
                }
            ],
            "ref_spans": [],
            "section": "M a n u s c r i p t"
        },
        {
            "text": "There are barriers to performing outpatient trials which must be solved. First, to implement a scalable early treatment strategy, widely available testing is needed. Home testing with self-sampling allows rapid diagnosis within a day of developing symptoms and avoids the need for personal protective equipment (PPE) utilization by health care staff. Recently, the United States Federal Drug Administration granted approval for home testing. Given the public health benefits of isolating cases, studies are making this available to citizens in cities with high burden of infection [24]. Self-quarantine will be more likely if people know they are infected, particularly given the economic incentive to continue working despite mild symptoms.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "M a n u s c r i p t"
        },
        {
            "text": "Second, because only 15% of infected people develop the clinically relevant outcome of hospitalization, proof of concepts trials must enroll large numbers of participants to be adequately powered. While such trials are required for licensure or to establish a new indication for a licensed agent, we propose smaller, rapid studies using viral shedding metrics and symptoms as surrogate endpoints for risk of progression to severe disease. Virologic endpoints are established surrogates of treatment efficacy for HIV, hepatitis B, hepatitis C, HSV-2, influenza and cytomegalovirus [13, [25] [26] [27] [28] . It is likely that a profound reduction in shedding early during SARS Co-V-2 infection will translate into prevention of oxygen need and hospitalization. We performed power calculations and identified that a 30-participant trial with blinded and equally sized placebo and treatment arms, would have 80% power to detect a 5-day reduction in shedding, or symptomatology. Once test-of-concept studies show antiviral and clinical potential, adaptive trials with clinical outcomes of hospitalization can be initiated. This approach is of special importance in high-risk populations such as senior centers and cancer centers.",
            "cite_spans": [
                {
                    "start": 580,
                    "end": 584,
                    "text": "[13,",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 585,
                    "end": 589,
                    "text": "[25]",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 590,
                    "end": 594,
                    "text": "[26]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 595,
                    "end": 599,
                    "text": "[27]",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 600,
                    "end": 604,
                    "text": "[28]",
                    "ref_id": "BIBREF26"
                }
            ],
            "ref_spans": [],
            "section": "M a n u s c r i p t"
        },
        {
            "text": "Smaller, and less expensive studies will allow a more diverse portfolio of agents to be rapidly screened. We propose urgent double-blind placebo-controlled clinical trials testing agents with biologic activity against SARS Co-V-2 in outpatients. Several small molecular agents demonstrate potency in vitro and in non-randomized studies in humans, including remdesivir, favipiravir, and selinexor [29] . Drug screening revealed many other FDA licensed agents which could be assessed [30] . Neutralizing antibody formulations are being developed and may have prophylactic value. Ideally, parallel studies would be conducted with each of these agents to provide clinicians with comparative efficacy, toxicity and dosing convenience data to optimize early treatment.",
            "cite_spans": [
                {
                    "start": 396,
                    "end": 400,
                    "text": "[29]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 482,
                    "end": 486,
                    "text": "[30]",
                    "ref_id": "BIBREF28"
                }
            ],
            "ref_spans": [],
            "section": "M a n u s c r i p t"
        },
        {
            "text": "Third, effective therapy, once discovered, must be delivered to an infected person's home. In the age of Amazon.com, this goal is achievable. Indeed, the Seattle flu study recently pioneered home delivery of baloxavir for early influenza treatment in a clinical trial [31] . Alternatively, a specialized clinic staffed by welltrained providers with optimal PPE, as well as those sero-immune to infection, could be established for intravenous infusions. The ongoing Antibody Mediated Prevention study for HIV in which over 40,000 doses of a neutralizing antibody or placebo have been infused in 4 continents, highlights the plausibility of such an intervention [32] . M a n u s c r i p t Finally, trials must specifically target minority populations, particularly those in underserved communities, who have been disproportionately impacted by the COVID-19 pandemic.",
            "cite_spans": [
                {
                    "start": 268,
                    "end": 272,
                    "text": "[31]",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 660,
                    "end": 664,
                    "text": "[32]",
                    "ref_id": "BIBREF30"
                }
            ],
            "ref_spans": [],
            "section": "M a n u s c r i p t"
        },
        {
            "text": "In Italy, overwhelmed physicians made a public plea for other countries to develop plans to keep patients at home [33] . Because the management of severe COVID-19 requires oxygen, ventilators, daily labs and radiology, the goal should be to avoid severe infection. To lower hospitalization rates during the inevitable second and third waves of the pandemic, incremental policies to flatten the curve will be necessary. We propose an adjunctive measure: make COVID-19 less fatal. Diagnose early. Treat early. Lower the hospitalization rate. Lower the death rate. M a n u s c r i p t A c c e p t e d M a n u s c r i p t",
            "cite_spans": [
                {
                    "start": 114,
                    "end": 118,
                    "text": "[33]",
                    "ref_id": "BIBREF31"
                }
            ],
            "ref_spans": [],
            "section": "M a n u s c r i p t"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Onder",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Rezza",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Brusaferro",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Analysis on 54 Mortality Cases of Coronavirus Disease 2019 in the Republic of Korea from",
            "authors": [],
            "year": 2020,
            "venue": "J Korean Med Sci",
            "volume": "35",
            "issn": "12",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "COVID-19 in a Long-Term Care Facility",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "M"
                    ],
                    "last": "Mcmichael",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Clark",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Pogosjans",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "MMWR Morb Mortal Wkly Rep",
            "volume": "69",
            "issn": "",
            "pages": "339--381",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "The Global Impact of COVID-19 and Strategies for Mitigation and Suppression. WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis: Abdul Latif Jameel Institute for Disease and Emergency Analytics",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Patrick",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "W"
                    ],
                    "last": "Walker",
                    "suffix": ""
                },
                {
                    "first": "Oliver",
                    "middle": [],
                    "last": "Watson",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Kissler",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Tedijanto",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Goldstein",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "H"
                    ],
                    "last": "Grad",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Lipsitch",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Science",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Respir Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "E"
                    ],
                    "last": "Young",
                    "suffix": ""
                },
                {
                    "first": "Swx",
                    "middle": [],
                    "last": "Ong",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Kalimuddin",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Viral dynamics in mild and severe cases of COVID-19",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "M"
                    ],
                    "last": "Yan",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Infect Dis",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Virological assessment of hospitalized patients with COVID-2019",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "W\u00f6lfel",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "M"
                    ],
                    "last": "Corman",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Guggemos",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Choi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Boudreault",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Xie",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Englund",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Corey",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Boeckh",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Blood",
            "volume": "117",
            "issn": "",
            "pages": "5050--5056",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Controlled Trial of Ebola Virus Disease Therapeutics",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mulangu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "E"
                    ],
                    "last": "Dodd",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "T"
                    ],
                    "last": "Davey",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "N Engl J Med",
            "volume": "381",
            "issn": "",
            "pages": "2293--303",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Sugaya",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Hirotsu",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "N Engl J Med",
            "volume": "379",
            "issn": "",
            "pages": "913--936",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Lundgren",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "G"
                    ],
                    "last": "Babiker",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Gordin",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "N Engl J Med",
            "volume": "373",
            "issn": "",
            "pages": "795--807",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Das",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "L"
                    ],
                    "last": "Chu",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Santos",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "PLoS One",
            "volume": "5",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "COVID-19) -United States",
            "authors": [],
            "year": 2019,
            "venue": "Severe Outcomes Among Patients with Coronavirus Disease",
            "volume": "69",
            "issn": "",
            "pages": "343--346",
            "other_ids": {
                "DOI": [
                    "10.15585/mmwr.mm6912e2"
                ]
            }
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Estimating the Risk of Human Herpesvirus 6 and Cytomegalovirus Transmission to Ugandan Infants from Viral Shedding in Saliva by Household Contacts",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "T"
                    ],
                    "last": "Mayer",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Krantz",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wald",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Viruses",
            "volume": "12",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Once-daily valacyclovir to reduce the risk of transmission of genital herpes",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Corey",
                    "suffix": ""
                },
                {
                    "first": "Wald",
                    "middle": [
                        "A"
                    ],
                    "last": "Patel",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "N Engl J Med",
            "volume": "350",
            "issn": "",
            "pages": "11--20",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Antiretroviral Therapy for the Prevention of HIV-1 Transmission",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Cohen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "Q"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mccauley",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "N Engl J Med",
            "volume": "375",
            "issn": "",
            "pages": "830--839",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebocontrolled trial",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Fry",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Goswami",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Nahar",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Lancet Infect Dis",
            "volume": "15",
            "issn": "",
            "pages": "654--62",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Florian",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Carter",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Gastroenterology",
            "volume": "144",
            "issn": "",
            "pages": "1450--1455",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Murray",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Elashoff",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "C"
                    ],
                    "last": "Iacono-Connors",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "A"
                    ],
                    "last": "Cvetkovich",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Struble",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "AIDS",
            "volume": "13",
            "issn": "",
            "pages": "797--804",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Natori",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alghamdi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Tazari",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Clin Infect Dis",
            "volume": "66",
            "issn": "",
            "pages": "617--648",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Agyemang",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Magaret",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Selke",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Johnston",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Corey",
                    "suffix": ""
                },
                {
                    "first": "Wald",
                    "middle": [
                        "A"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Infect Dis",
            "volume": "218",
            "issn": "",
            "pages": "1691--1700",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Compounds with therapeutic potential against novel respiratory 2019 coronavirus",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Martinez",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Antimicrob Agents Chemother",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "A SARS-CoV-2 protein interaction map reveals targets for drug repurposing",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Gordon",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Jang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Bouhaddou",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "The Seattle Flu Study: A Community-Based Study of Influenza",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Chu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Boeckh",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Englund",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "OFID October",
            "volume": "6",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "B"
                    ],
                    "last": "Gilbert",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Juraska",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Decamp",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Stat Commun Infect Dis",
            "volume": "9",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "At the Epicenter of the Covid-19 Pandemic and Humanitarian Crises in Italy: Changing Perspectives on Preparation and Mitigation",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Nacoti",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Ciocca",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Giupponi",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "NEJM catalyst",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/CAT.20.0080"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Schematic of SARS Co-V-2 infection in a symptomatic person.",
            "latex": null,
            "type": "figure"
        }
    },
    "back_matter": [
        {
            "text": "A c c e p t e d M a n u s c r i p t",
            "cite_spans": [],
            "ref_spans": [],
            "section": "annex"
        }
    ]
}